News
Latest news related to non-animal research
-
28 January 2026AI to assess chemicals, India: AI Center of excellence, The largest dataset for Virtual Cell Modeling, Vascularised organoids, and more
NEWS, REPORTS & POSITION STATEMENTS 1. Challenges and opportunities for human OOC in FDA assessments and pharma pipelines The US Food and Drug Administration recently announced a plan to phase out animal-testing requirements for drug assessments based on advances in […]
Read more -
21 January 2026Animal-free endotoxins test, Common principles for AI, Bioprinted organs on demand, Multi-omics qualification of an OOC model, and more
NEWS, REPORTS & POSITION STATEMENTS 1. Endotoxin testing milestone reached with European Pharmacopoeia’s animal shift From 1 January 2026, EU pharmaceutical manufacturers will need to use advanced alternatives such as the Monocyte-Activation Test (MAT) or the Bacterial Endotoxins Test (BET) […]
Read more -
14 January 2026EU: NAMs trainings, US federal NAMs milestones, Bioprinted pregnant human uterine and more
NEWS, REPORTS & POSITION STATEMENTS 1. Mapping existing NAM‑related training initiatives across Europe Training and capacity building are essential for the successful regulatory uptake of New Approach Methodologies (NAMs), which is also a core focus of the NAMWISE project. CEHTRA […]
Read more -
8 January 2026FDA Modernization Act 3.0, EU Biotech Act, FDA qualifies first AI drug development tool, NWO grants, Multimodal AI & virtual population, and more
NEWS, REPORTS & POSITION STATEMENTS 1. U.S. Senate passes FDA Modernization Act 3.0 Last December, U.S Senate Republicans and Democrats united to pass the FDA Modernization Act 3.0 (FDAMA 3.0), reaffirming strong bipartisan support for the government-wide shift toward modern, […]
Read more -
16 December 2025Political agreement on new EU pharmaceutical legislation, Interlaboratory validation of NAM, Global Exposome Summit, and more
NEWS, REPORTS & POSITION STATEMENTS 1. Opportunities and insights from pharmaceutical companies on the current use of NAMs in nonclinical safety assessment To foster broader adoption of NAMs, the Biotechnology Innovation Organization surveyed pharma/biotech companies about NAM usage and collected […]
Read more
